Beth Ann G Coller
Affiliation: Merck Research Laboratories
- Dengue vaccines: progress and challengesBeth Ann G Coller
Vaccines Research, WP17 2131, Merck and Company, 770 Sumneytown Pike, P O Box 4, West Point, PA 19486, United States
Curr Opin Immunol 23:391-8. 2011....
- The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced diseaseBeth Ann G Coller
Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, United States
Vaccine 29:7267-75. 2011..Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review...
- Preclinical and clinical development of a dengue recombinant subunit vaccineSusan B Manoff
Merck and Co, Inc, Kenilworth, NJ, United States
Vaccine 33:7126-34. 2015..Both the 10μg DEN1-80E and the 50μg DEN1-80E formulations with Alhydrogel™ were generally well tolerated. ..